Publication date: May 05, 2024
Between 2 and 8. 5% of patients who recover from COVID-19 do not develop antibodies, and the durability of IgG antibodies is under scrutiny. Therefore, the presence and persistence of IgM and IgG antibodies were evaluated in a group of patients diagnosed with SARS-CoV-2 from May to August 2020. Out of 2199 suspected COVID-19 cases, 1264 were confirmed for SARS-CoV-2 by rRT-PCR; 328 consented to participate in the study, with 220 participants followed for 9 months, including 124 men (56%) and 96 women (44%). The primary symptoms were headache, dry cough, and fever. IgG antibodies developed in 95% of patients within 4 weeks post-diagnosis, and a second evaluation at 9 months showed that 72. 7% still had detectable IgG antibodies. The presence of IgM in one individual (0. 45%) suggested the possibility of reinfection.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Antibodies | antibody responses |
| August | COVID-19 reinfection |
| Headache | COVID-19 serological testing |
| Pcr | seroconversion |
| Weeks |